MegaPro Biomedical Co. Ltd.

MegaPro MPB-1523, a MRI contrast agent for focal liver lesion, just completed its End of Phase 2 (EOP2) meeting with U.S. FDA and will aim to the IND of Phase III clinical trials.

MegaPro Biomedical MPB-1523 Clinical Phase II Trial Results Published in International Journals

MegaPro Biomedical MPB-1734 Receives Composition Patent for New Dosage Form of Anticancer Drug which enhanced the immune-combination therapy

MegaPro Successfully Completes the biological evaluations of IOP as Vaccine Adjuvant T cell mediated Immunity is Substantially Enhanced, Improving the Efficacy of Vaccines

MegaPro, CCPC, and Wellbridge Jointly Establishes an Inhalation Dosage Form Company

New dosage form (or formulation) of anticancer drug MPB-1734 passes the US FDA clinical I/IIa IND application